更高剂量的tisagenlecleucel与改善的结局相关:来自儿科真实世界CAR联盟的报告
该回顾性研究收集了儿科真实世界CAR联盟成员机构的185例接受商业tisagenlecleucel输注的患者数据,中位活转导CAR T细胞剂量为1.7×10^6/kg。按剂量四分位分组后,接受较高剂量tisagenlecleucel的患者总生存、无事件生存和无复发生存均改善(P值分别为.031、.0079和.0045),且较高剂量未增加毒性。
要点
- 接受较高剂量tisagenlecleucel的患者总生存改善(P = .031)。
- 接受较高剂量tisagenlecleucel的患者无事件生存改善(P = .0079)。
- 接受较高剂量tisagenlecleucel的患者无复发生存改善(P = .0045)。
核心结论
- 接受较高剂量tisagenlecleucel的患者总生存、无事件生存和无复发生存均改善,且较高剂量未增加毒性。
- 由于当前tisagenlecleucel说明书剂量范围仍然宽泛,本研究结果对在获批剂量范围内靶向较高细胞剂量以优化患者获得长期缓解的潜力具有意义。
研究设计与样本
- 回顾性数据收集自儿科真实世界CAR联盟成员机构,纳入185例接受商业tisagenlecleucel输注的患者。
- 为评估细胞剂量影响,将应答者按剂量四分位分组:0.134至1.300×10^6(n = 48 [27%])、1.301至1.700×10^6(n = 46 [26%])、1.701至2.400×10^6(n = 43 [24%])和2.401至5.100×10^6(n = 43 [24%])。
- 中位活转导CAR T细胞剂量为1.7×10^6 CAR T细胞/kg。
主要发现
- 接受较高剂量tisagenlecleucel的患者总生存改善(P = .031)。
- 接受较高剂量tisagenlecleucel的患者无事件生存改善(P = .0079)。
- 接受较高剂量tisagenlecleucel的患者无复发生存改善(P = .0045)。
- 较高剂量tisagenlecleucel与毒性增加无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Remarkable complete response rates have been shown with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy targeting CD19, in patients up to age 26 years with refractory/relapsed B-cell acute lymphoblastic leukemia; it is US Food and Drug Administration approved for this indication. Currently, patients receive a single dose of tisagenlecleucel across a wide dose range of 0.2 to 5.0 × 106 and 0.1 to 2.5 × 108 CAR T cells per kg for patients ≤50 and >50 kg, respectively. The effect of cell dose on survival and remission is not yet well established. Our primary goal was to determine if CAR T-cell dose affects overall survival (OS), event-free survival (EFS), or relapse-free-survival (RFS) in tisagenlecleucel recipients. Retrospective data were collected from Pediatric Real World CAR Consortium member institutions and included 185 patients infused with commercial tisagenlecleucel. The median dose of viable transduced CAR T cells was 1.7 × 106 CAR T cells per kg. To assess the impact of cell dose, we divided responders into dose quartiles: 0.134 to 1.300 × 106 (n = 48 [27%]), 1.301 to 1.700 × 106 (n = 46 [26%]), 1.701 to 2.400 × 106 (n = 43 [24%]), and 2.401 to 5.100 × 106 (n = 43 [24%]). OS, EFS, and RFS were improved in patients who received higher doses of tisagenlecleucel (P = .031, .0079, and .0045, respectively). Higher doses of tisagenlecleucel were not associated with increased toxicity. Because the current tisagenlecleucel package insert dose range remains broad, this work has implications in regard to targeting higher cell doses, within the approved dose range, to optimize patients' potential for long-standing remission.
引用
- Stefanski HE, Eaton A, Baggott C, et al. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023. PMID: 35938863. doi:10.1182/bloodadvances.2022007246
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。